These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18622632)

  • 41. Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis.
    Segarra Medrano A; Vila Presas J; Pou Clavé L; Majó Masferrer J; Camps Doménech J
    Nefrologia; 2011; 31(3):286-91. PubMed ID: 21468162
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial.
    Choi JY; Kim DK; Kim YW; Yoo TH; Lee JP; Chung HC; Cho KH; An WS; Lee DH; Jung HY; Cho JH; Kim CD; Kim YL; Park SH
    J Korean Med Sci; 2018 Feb; 33(9):e74. PubMed ID: 29441742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
    Bornhäuser M; Schuler U; Pörksen G; Naumann R; Geissler G; Thiede C; Schwerdtfeger R; Ehninger G; Thiede HM
    Transplantation; 1999 Feb; 67(4):499-504. PubMed ID: 10071016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
    Sinha A; Gupta A; Kalaivani M; Hari P; Dinda AK; Bagga A
    Kidney Int; 2017 Jul; 92(1):248-257. PubMed ID: 28318625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Mycophenolate mofetil (MMF) as the first choice immunosuppressive drug in treatment of steroid-dependent nephrotic syndrome in children].
    Ogarek I; Szczęsny-Choruz E; Wierzchowska-Słowiaczek E; Kwinta-Rybicka J; Stec Z; Moczulska A; Wilkosz K; Drożdż D
    Pol Merkur Lekarski; 2018 Apr; 44(262):192-195. PubMed ID: 29775447
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of oral cyclophosphamide versus mycophenolate mofetil in childhood nephrotic syndrome: an open-label comparative study.
    Dhooria GS; Bhargava S; Bhat D; Pooni PA; Goel N; Kakkar S
    BMC Nephrol; 2024 Sep; 25(1):296. PubMed ID: 39251984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil.
    Tedoriya T; Keogh AM; Kusano K; Savdie E; Hayward C; Spratt PM; Wilson M; Macdonald PS
    J Heart Lung Transplant; 2002 Sep; 21(9):976-82. PubMed ID: 12231368
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome.
    Barletta GM; Smoyer WE; Bunchman TE; Flynn JT; Kershaw DB
    Pediatr Nephrol; 2003 Aug; 18(8):833-7. PubMed ID: 12774223
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
    Pham PT; Pham PC
    Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
    Thierry A; Le Meur Y; Ecotière L; Abou-Ayache R; Etienne I; Laurent C; Vuiblet V; Colosio C; Bouvier N; Aldigier JC; Rerolle JP; Javaugue V; Gand E; Bridoux F; Essig M; Hurault de Ligny B; Touchard G
    Transpl Int; 2016 Jan; 29(1):23-33. PubMed ID: 26729582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity.
    Filler G; Gellermann J; Zimmering M; Mai I
    Transpl Int; 2000; 13(3):201-6. PubMed ID: 10935703
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.
    Stegall MD; Wachs ME; Everson G; Steinberg T; Bilir B; Shrestha R; Karrer F; Kam I
    Transplantation; 1997 Dec; 64(12):1755-60. PubMed ID: 9422416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical efficacy of mycophenolate mofetil versus levamisole therapy in frequently relapsing and steroid dependent childhood nephrotic syndrome - A retrospective comparative analysis.
    Sharma S; Kalra S; Shukla S; Sharma P
    Nephrology (Carlton); 2022 Sep; 27(9):758-762. PubMed ID: 35619554
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mycophenolate mofetil introduction stabilizes and subsequent cyclosporine A reduction slightly improves kidney function in pediatric renal transplant patients: a retrospective analysis.
    Benz K; Plank C; Griebel M; Montoya C; Dötsch J; Klare B
    Pediatr Transplant; 2006 May; 10(3):331-6. PubMed ID: 16677357
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The treatment of relapse in adults with minimal change nephrotic syndrome: myths and facts.
    Shigidi MM
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):10-7. PubMed ID: 21196608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
    Choudhry S; Bagga A; Hari P; Sharma S; Kalaivani M; Dinda A
    Am J Kidney Dis; 2009 May; 53(5):760-9. PubMed ID: 19268410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
    Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
    Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis.
    Aragon E; Resontoc LP; Chan YH; Lau YW; Tan PH; Loh HL; Ng KH; Yap HK
    Lupus; 2016 Apr; 25(4):399-406. PubMed ID: 26537422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.